Colin Garvie, Ph.D.

Colin Garvie is a senior group leader in the Center for the Development of Therapeutics (CDoT) at the Broad Institute of MIT and Harvard. He leads the protein science group that seeks to facilitate the development of therapeutics against a particular disease by producing and characterizing the protein targets that are causative agents in the disease. Currently, he is directly involved in supporting two oncology-related projects.

Prior to joining the Broad Institute in 2012, Garvie worked in Roche’s Discovery Technology division, leading a group responsible for generating the (protein) therapeutic targets for the oncology platform and working closely with the assay development and structural biology groups. This experience followed five years as an assistant professor and research group leader at the University of Maryland Baltimore County, where Garvie developed and directed a research program in structural biophysics. The main focus of his group’s research was the structure of a multi-protein complex required for initiating the mammalian immune response.

Garvie obtained his Ph.D. at the University of Leeds under the mentorship of Simon Phillips, using X-ray crystallography to study sequence-specific recognition of DNA by transcriptional regulators. He also holds a B.Sc. in chemistry from the University of Glasgow. He continued his interest in the molecular details of gene regulation in more complicated systems as a Howard Hughes Post-Doctoral Research Fellow at Johns Hopkins University School of Medicine under the mentorship of Cynthia Wolberger.

Contact Colin Garvie at cgarvie@broadinstitute.org.